Syneos Health downgraded by Guggenheim
$SYNH
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Guggenheim downgraded Syneos Health from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2023 | $30.00 → $28.00 | Neutral → Underweight | JP Morgan |
| 1/17/2023 | $30.00 → $25.00 | Overweight → Underweight | Barclays |
| 1/13/2023 | $25.00 | Overweight → Underweight | Barclays |
| 12/14/2022 | $66.00 → $38.00 | Buy → Neutral | Mizuho |
| 11/7/2022 | $55.00 → $27.00 | Outperform → In-line | Evercore ISI |
| 10/18/2022 | $85.00 → $53.00 | Overweight → Neutral | JP Morgan |
| 9/14/2022 | Buy → Neutral | Guggenheim | |
| 9/7/2022 | $68.00 | Neutral | UBS |